SOTAGLIFLOZIN SIGNIFICANTLY REDUCES CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN THE SCORED TRIAL

• Ngā kaituhi matua: Deepak L. Bhatt (Author), Michael Szarek (Author), Bertram Pitt (Author), Ph Gabriel Steg (Author), on behalf of the SCORED Investigators (Author)
• Hōputu: Pukapuka
• I whakaputaina: Elsevier, 2023-03-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Therapeutic Area: Diabetes Background: SGLT2 inhibitors have had a remarkable effect on heart failure, but variable effects on ischemic endpoints. In the SCORED trial, sotagliflozin, a dual SGLT1 and 2 inhibitor, reduced total cardiovascular (CV) deaths, heart failure hospitalizations, and urgent he...